SURE-01/02: Perioperative SG Alone, With Pembrolizumab for Patients With MIBC

Antonio Cigliola, MD, of IRCCS San Raffaele Hospital, and Amanda Nizam, MD, of Cleveland Clinic, discuss the implications of the reported SURE-01/02 study interim results.

These investigations looked at perioperative sacituzumab govitecan alone or in combination with pembrolizumab for patients with muscle-invasive bladder cancer.